<DOC>
	<DOCNO>NCT01056783</DOCNO>
	<brief_summary>This randomise , double blind , placebo control , parallel group evaluation effect OC000459 give orally eight week active eosinophilic esophagitis .</brief_summary>
	<brief_title>Proof Concept Study OC000459 Eosinophilic Esophagitis</brief_title>
	<detailed_description />
	<mesh_term>Esophagitis</mesh_term>
	<mesh_term>Eosinophilic Esophagitis</mesh_term>
	<mesh_term>Indoleacetic Acids</mesh_term>
	<criteria>Previously diagnose symptomatic isolated eosinophilic esophagitis . Relevant eosinophil tissue inflammation demonstrate mean eosinophil load &gt; = 20 eos/hpf 8 biopsy baseline visit . Able swallow placebo medication successfully supervision clinic Free medication EoE ( include topical steroid ) least 2 week prior baseline free systemic steroid least 90 day screen . A protonpump inhibitor allow require treatment secondary acid reflux . Other cause esophagitis ( GERD , peptic ulceration , infection etc . ) Other cause eosphagaeal generalize eosinophilia ( i.e . hypereosinophilic syndrome , parasitic infection , GERD ) The patient 's EoE dependant level seasonal allergens patient 's participation study occur allergy season . History abnormal gastric duodenal eosinophilia ( e.g . HES , Churg Strauss vasculitis , EG parasitic infection ) Receipt forbidden prescribe counter medication within 4 week prior baseline visit duration trial , include vitamin herbal remedy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>EoE</keyword>
</DOC>